Press Releases

Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic

Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategies Acquisition further expands Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing

Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 2022 Achieve preliminary proof-of-concept for NTLA-2002 in patients with hereditary angioedema (HAE) based on ongoing

CAMBRIDGE, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the

• Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases
   
• Kyverna to lead and fund preclinical and clinical development; Intellia to receive option

CAMBRIDGE, Mass. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the appointment of Derek Hicks to a newly created

NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) to enter clinical study CAMBRIDGE, Mass. , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy CAMBRIDGE, Mass. , Nov. 22, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United

CAMBRIDGE, Mass. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics , Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , today announced the presentation of data from its

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022 Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) On track to